Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh.
Sci Rep. 2024 Sep 2;14(1):20380. doi: 10.1038/s41598-024-71733-4.
Xanthine oxidase (XO) is an enzyme that converts hypoxanthine into xanthine and xanthine into uric acid, which is then eliminated by the kidneys. Serum XO has been linked to diabetes, hypertension, liver dysfunction, and cardiovascular diseases. However, limited information exists on the relationship between serum XO activity and MetS. This study aimed to analyze the relationship between XO activity and metabolic syndrome (MetS) and its components in an adult population group in Bangladesh A total of 601 participants aged ≥18 years were included in the study. MetS was defined based on the criteria set by the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III). Serum XO activity was measured using the enzyme-linked immunosorbent assay (ELISA), while other biochemical parameters were measured using colorimetric methods. The relationship between serum XO and MetS levels was determined through multivariate logistic regression analysis. Serum XO activity was found to be significantly higher in females (6.17 ± 3.77 U/L) as compared to males (4.00 ± 2.77 U/L) (p < 0.001). Furthermore, participants with MetS had significantly higher mean levels of serum XO (5.34 ± 3.39 U/L) than those without MetS (3.86 ± 2.90 U/L) (p < 0.001). The prevalence of MetS and its components, such as blood pressure and blood glucose increased across the XO quartiles (p < 0.001). Regression analysis indicated that XO activity was significantly and independently associated with the prevalence of MetS (at least p < 0.05 for all cases) and its components, including elevated blood pressure, high blood glucose, and low HDL-C (at least p < 0.05 for all cases). In conclusion, individuals with MetS had significantly higher XO levels than those without MetS. Serum XO activity showed an independent association with MetS and some of its components. Therefore, XO might serve as a useful marker of MetS. Prospective studies are needed to determine the underlying mechanisms linking XO and MetS.
黄嘌呤氧化酶(XO)是一种将次黄嘌呤转化为黄嘌呤,将黄嘌呤转化为尿酸的酶,然后尿酸通过肾脏排出体外。血清 XO 与糖尿病、高血压、肝功能障碍和心血管疾病有关。然而,关于血清 XO 活性与代谢综合征(MetS)之间的关系,信息有限。本研究旨在分析孟加拉国成年人群中 XO 活性与代谢综合征(MetS)及其成分之间的关系。共纳入 601 名年龄≥18 岁的参与者。代谢综合征的定义基于美国国家胆固醇教育计划-成人治疗专家组 III(NCEP-ATP III)的标准。使用酶联免疫吸附试验(ELISA)测量血清 XO 活性,而其他生化参数则使用比色法测量。通过多变量逻辑回归分析确定血清 XO 与 MetS 水平之间的关系。结果显示,女性的血清 XO 活性显著高于男性(6.17±3.77 U/L 比 4.00±2.77 U/L)(p<0.001)。此外,患有代谢综合征的参与者的血清 XO 水平明显高于无代谢综合征的参与者(5.34±3.39 U/L 比 3.86±2.90 U/L)(p<0.001)。随着 XO 四分位区间的升高,代谢综合征及其组分(如血压和血糖)的患病率也随之升高(p<0.001)。回归分析表明,XO 活性与代谢综合征的患病率显著相关(所有病例至少 p<0.05),与代谢综合征的某些成分(包括血压升高、高血糖和低 HDL-C)显著相关(所有病例至少 p<0.05)。总之,患有代谢综合征的个体的 XO 水平明显高于无代谢综合征的个体。血清 XO 活性与代谢综合征及其某些成分独立相关。因此,XO 可能是代谢综合征的一个有用标志物。需要前瞻性研究来确定 XO 与代谢综合征之间的潜在机制。